Padmanee ‘Pam’ Sharma, M.D., Ph.D.

Co-Director, Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center

Immunology, Immunotherapy, GU Medical Oncology


BA - Boston University

MA - Boston University

MD/PhD - Pennsylvania State University College of Medicine

Residency - New York Presbyterian Hospital, Weill Cornell Medical Center

Postdoctoral Fellow - Memorial Sloan-Kettering Cancer Center


MD Anderson Cancer Center Faculty Scholar Award, 2012

MD Anderson Cancer Center Emil Frei, III Award for Excellence in Translational Research, 2016

MD Anderson Cancer Center The Julie & Ben Rogers Award for Excellence in Research, 2018

William B. Coley Award in Tumor Immunology by the Cancer Research Institute, 2018

American Society for Clinical Investigation (ASCI), 2018

Women in Science with Excellence (WISE) Honoree, BioHouston, 2020


Co-Founder: Apricity Health, Jounce Therapeutics (NASDAQ: JNCE), Agilicell

Scientific Advisory Board: Amgen, Astellas, Kite Pharma (acquired by Gilead), Jounce Therapeutics (NASDAQ: JNCE), Forty Seven, Inc., AstraZeneca Advisory Board, Bristol Myers Squibb Immunology Biomarker Advisory Board, GSK Biomarkers Advisory Board, Hummingbird Bioscience, BioMx, Dragonfly Therapeutics, Codiak Biosciences, Lava Therapuetics, Glympse Bio

MEMBER OF Investment Committee

Associated Portfolio Companies

No items found.